Skip to main content

Transferrin

Transferrin is a hepatically synthesized β-globulin (MW ~ 79.5 kDa) with a half-life of ~ 7–8 days and a normal serum concentration of 200–400 mg/dL.[1][2] Its primary physiological role is iron transport — each molecule binds two Fe³⁺ atoms and delivers them to cells via transferrin-receptor-mediated endocytosis, cycling 100–200 times during its lifespan.[1][3] Like albumin and prealbumin, it is a negative acute-phase protein and a poor marker of nutritional status when used in isolation.[4][5]

Transferrin in Iron Metabolism​

Transferrin is central to iron homeostasis and is most commonly encountered clinically through its derived indices:

  • Transferrin saturation (TSAT) = serum iron ÷ TIBC × 100. Normal range 16–45%; values < 16% suggest iron deficiency, > 50% suggest iron overload. First-line screening test for hereditary hemochromatosis.[2][6]
  • Total iron-binding capacity (TIBC) is linearly correlated with transferrin concentration and is elevated in true iron deficiency.[7]
  • Transferrin is increased in iron deficiency (upregulated to maximize iron capture), pregnancy, and oral contraceptive use; decreased in iron overload, inflammation, infection, liver disease, malignancy, nephrotic syndrome, and malnutrition.[2][8]

This bidirectional response to iron status and inflammation creates a fundamental interpretive challenge — particularly in distinguishing iron-deficiency anemia (IDA) from anemia of chronic disease (ACD). The soluble transferrin receptor (sTfR) and the sTfR/log ferritin index have emerged as superior tools for this differentiation, as sTfR is largely unaffected by inflammation.[9]

Transferrin as a Nutritional Marker — Same Limitations as Albumin and Prealbumin​

The ASPEN 2021 position paper explicitly includes transferrin alongside albumin and prealbumin as a negative acute-phase protein whose serum concentration declines during inflammation due to hepatic reprioritization of protein synthesis.[4] Key evidence against its use as a nutritional marker:

  • Roza 1984 — While transferrin correlated with body cell mass at the population level, the false-positive rate was 60% and the false-negative rate was 31% for individual patients. Transferrin did not change significantly after 2 weeks of TPN despite significant changes in nutritional state.[10]
  • Ingenbleek 1975 — Transferrin had only intermediate sensitivity for detecting malnutrition, inferior to prealbumin. Iron deficiency and protein deficiency exert "contradictory impulses" on transferrin synthesis (iron deficiency raises it, protein deficiency lowers it), partially invalidating it as an index of protein depletion alone.[5]
  • Morlese 1997 — In children with severe protein-energy malnutrition, transferrin kinetic studies showed that plasma transferrin was "not a very good indicator of protein nutritional status," with only fair correlations to indices of wasting.[11]

Transferrin as a Biomarker of Liver Function​

An emerging role for transferrin is as a biomarker of hepatocyte function and HNF4α activity. Serum transferrin correlates with hepatic transferrin expression (r = 0.51, P = 0.01) and is independently predictive of mortality in patients with liver failure.[12] In alcoholic cirrhosis, transferrin synthesis is significantly decreased (0.9 vs 1.8 mg/kg/hr in controls).[13] This positions transferrin as a potential surrogate of liver-failure severity, complementing traditional markers like albumin and bilirubin.

Transferrin in Hemodialysis Patients​

In the hemodialysis population, TIBC-estimated transferrin correlates with the Subjective Global Assessment (SGA). Well-nourished patients had significantly higher TIBC (276 mg/dL) compared with moderately (217 mg/dL) and poorly nourished (176 mg/dL) patients.[14] However, decreased TIBC in malnourished dialysis patients can falsely elevate transferrin saturation, potentially masking iron deficiency.[14]

Summary Comparison with Albumin and Prealbumin​

FeatureAlbuminPrealbuminTransferrin
Half-life~ 20 days~ 2 days~ 7–8 days
Normal range3.5–5.0 g/dL20–40 mg/dL200–400 mg/dL
Negative acute-phase proteinYesYesYes
Reliable nutritional markerNoNoNo
Unique confoundersCapillary leak, dilutionFalsely elevated in renal failureBidirectional response to iron status
Best clinical usePrognostic marker, inflammation severityInflammation resolution (with CRP)Iron metabolism, liver function

Reconstructive Relevance​

Transferrin is rarely the right marker for a nutritional decision in reconstructive urology / urogynecology. Its real value in this patient population is iron-status workup in the preoperative setting:

  • Major reconstruction with expected blood loss (radical cystectomy + urinary diversion, complex prolapse, gender-affirming phalloplasty, RPLND-context reconstruction) — preoperative IDA is common and modifiable. TSAT < 20% + ferritin < 100 ng/mL (or < 300 ng/mL with TSAT < 20% in chronic disease) is the operational threshold for IV iron supplementation under most PBM (patient blood management) protocols.
  • Distinguishing IDA from ACD — In cancer-survivorship and chronic-illness populations (radiation cystitis, post-cystectomy diversion, cancer-related anemia), use sTfR / log ferritin index rather than transferrin alone. ACD with superimposed IDA is the trap.
  • Hemodialysis patients undergoing reconstruction — Do not rely on TSAT alone; check serum ferritin and use SGA for nutritional status. Decreased TIBC in malnourished dialysis patients can falsely normalize TSAT.
  • Liver-disease patients facing complex reconstruction — Low transferrin may carry additional prognostic information about hepatic synthetic capacity beyond albumin and INR; consider in the cirrhotic patient being worked up for elective urinary diversion or revision surgery.
  • Do not use transferrin as a standalone nutritional marker. For malnutrition diagnosis, use validated tools (NRS-2002, GLIM, SGA) and nutrition-focused physical examination.

See Also​

References​

1. Yousefpour P, Chilkoti A. "Co-opting biology to deliver drugs." Biotechnology and Bioengineering. 2014;111(9):1699–1716. doi:10.1002/bit.25307

2. Goyal A, Zheng Y, Albenberg LG, et al. "Anemia in Children With Inflammatory Bowel Disease: A Position Paper by the IBD Committee of the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition." Journal of Pediatric Gastroenterology and Nutrition. 2020;71(4):563–582. doi:10.1097/MPG.0000000000002885

3. Kawabata H. "Transferrin and Transferrin Receptors Update." Free Radical Biology & Medicine. 2019;133:46–54. doi:10.1016/j.freeradbiomed.2018.06.037

4. Evans DC, Corkins MR, Malone A, et al. "The Use of Visceral Proteins as Nutrition Markers: An ASPEN Position Paper." Nutrition in Clinical Practice. 2021;36(1):22–28. doi:10.1002/ncp.10588

5. Ingenbleek Y, Van Den Schrieck HG, De Nayer P, De Visscher M. "Albumin, Transferrin and the Thyroxine-Binding Prealbumin/Retinol-Binding Protein (TBPA-RBP) Complex in Assessment of Malnutrition." Clinica Chimica Acta. 1975;63(1):61–67. doi:10.1016/0009-8981(75)90379-4

6. Szőke D, Panteghini M. "Diagnostic Value of Transferrin." Clinica Chimica Acta. 2012;413(15–16):1184–1189. doi:10.1016/j.cca.2012.04.021

7. Kasvosve I, Delanghe J. "Total Iron Binding Capacity and Transferrin Concentration in the Assessment of Iron Status." Clinical Chemistry and Laboratory Medicine. 2002;40(10):1014–1018. doi:10.1515/CCLM.2002.176

8. Garcia-Casal MN, Pasricha SR, Martinez RX, Lopez-Perez L, Peña-Rosas JP. "Serum or Plasma Ferritin Concentration as an Index of Iron Deficiency and Overload." Cochrane Database of Systematic Reviews. 2021;5:CD011817. doi:10.1002/14651858.CD011817.pub2

9. Skikne BS, Punnonen K, Caldron PH, et al. "Improved differential diagnosis of anemia of chronic disease and iron deficiency anemia: A prospective multicenter evaluation of soluble transferrin receptor and the sTfR/log ferritin index." American Journal of Hematology. 2011;86(11):923–927. doi:10.1002/ajh.22108

10. Roza AM, Tuitt D, Shizgal HM. "Transferrin — a Poor Measure of Nutritional Status." JPEN. Journal of Parenteral and Enteral Nutrition. 1984;8(5):523–528. doi:10.1177/0148607184008005523

11. Morlese JF, Forrester T, Del Rosario M, Frazer M, Jahoor F. "Transferrin Kinetics Are Altered in Children With Severe Protein-Energy Malnutrition." The Journal of Nutrition. 1997;127(8):1469–1474. doi:10.1093/jn/127.8.1469

12. Guldiken N, Argemi J, Gurbuz B, et al. "Serum Transferrin as a Biomarker of Hepatocyte Nuclear Factor 4 Alpha Activity and Hepatocyte Function in Liver Diseases." BMC Medicine. 2021;19(1):39. doi:10.1186/s12916-021-01917-6

13. Potter BJ, Chapman RW, Nunes RM, Sorrentino D, Sherlock S. "Transferrin Metabolism in Alcoholic Liver Disease." Hepatology. 1985;5(5):714–721. doi:10.1002/hep.1840050503

14. Kalantar-Zadeh K, Kleiner M, Dunne E, et al. "Total Iron-Binding Capacity-Estimated Transferrin Correlates With the Nutritional Subjective Global Assessment in Hemodialysis Patients." American Journal of Kidney Diseases. 1998;31(2):263–272. doi:10.1053/ajkd.1998.v31.pm9469497